{
    "eid": "2-s2.0-85131069161",
    "title": "Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern",
    "cover-date": "2022-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Virology",
            "@code": "2406",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "COVID-19",
        "immunogenicity",
        "plant-produced recombinant protein",
        "receptor-binding domain",
        "SARS-CoV-2",
        "subunit vaccine",
        "variant vaccine"
    ],
    "authors": [
        "Narach Khorattanakulchai",
        "Suwimon Manopwisedjaroen",
        "Kaewta Rattanapisit",
        "Chalisa Panapitakkul",
        "Taratorn Kemthong",
        "Nutchanat Suttisan",
        "Kanjana Srisutthisamphan",
        "Suchinda Malaivijitnond",
        "Arunee Thitithanyanont",
        "Anan Jongkaewwattana",
        "Balamurugan Shanmugaraj",
        "Waranyoo Phoolcharoen"
    ],
    "citedby-count": 3,
    "ref-count": 49,
    "ref-list": [
        "Clinical features of patients infected with 2019 novel coronavirus in wuhan, China",
        "Subunit vaccines against emerging pathogenic human coronaviruses",
        "Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine",
        "Recombinant protein vaccines, a proven approach against coronavirus pandemics",
        "Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine",
        "Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials",
        "New SARS-CoV-2 variants - clinical, public health, and vaccine implications",
        "SARS-CoV-2 variants of concern are emerging in India",
        "Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review",
        "SARS-CoV-2 omicron variant: could it be another threat?",
        "Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum",
        "Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization",
        "Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients",
        "Addressing demand for recombinant biopharmaceuticals in the COVID-19 era",
        "Potential applications of plant biotechnology against SARS-CoV-2",
        "A comprehensive overview on the production of vaccines in plant-based expression systems and the scope of plant biotechnology to combat against SARS-CoV-2 virus pandemics",
        "Contributions of the international plant science community to the fight against human infectious diseases - part 1: epidemic and pandemic diseases",
        "Potential for developing plant-derived candidate vaccines and biologics against emerging coronavirus infections",
        "Magnifection: a new platform for expressing recombinant vaccines in plants",
        "Plant-based vaccines: the way ahead?",
        "Recent development and future prospects of plant-based vaccines",
        "Plant molecular farming: a viable platform for recombinant biopharmaceutical production",
        "SARS-CoV-2 vaccines: current trends and prospects of developing plant-derived vaccines",
        "Monoclonal antibodies B38 and H4 produced in Nicotiana benthamiana neutralize SARS-CoV-2 in vitro",
        "Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana",
        "Plant-produced receptor-binding domain of SARS-CoV-2 elicits potent neutralizing responses in mice and non-human primates",
        "Immunogenicity studies of plant-produced SARS-CoV-2 receptor binding domain-based subunit vaccine candidate with different adjuvant formulations",
        "Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model",
        "A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses",
        "Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies",
        "Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants",
        "A statistically defined endpoint titer determination method for immunoassays",
        "CoronaVac induces lower neutralising activity against variants of concern than natural infection",
        "Characterisation of SARS-CoV-2 lentiviral pseudotypes and correlation between pseudotype-based neutralisation assays and live virus-based micro neutralisation assays",
        "Pseudotype neutralization assays: from laboratory bench to data analysis",
        "Effects of common mutations in the SARS-CoV-2 spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics",
        "The D614G mutations in the SARS-CoV-2 spike protein: implications for viral infectivity, disease severity and vaccine design",
        "The N501Y spike substitution enhances SARS-CoV-2 infection and transmission",
        "Association of E484K spike protein mutation with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated persons: Maryland, January\u2013May 2021",
        "Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany",
        "Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization",
        "Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7",
        "Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nakhon Pathom",
            "@id": "60012718",
            "affilname": "Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012718",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60011947",
            "affilname": "Thailand National Center for Genetic Engineering and Biotechnology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011947",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "127622148",
            "affilname": "Ltd",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127622148",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Baiya Phytopharm Co., Ltd.",
        "Chulalongkorn University"
    ]
}